- Home
- PMVP vs CNTB Comparison
PMVP vs CNTB Comparison
Compare PMVP & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMVP
- CNTB
- Stock Information
- Founded
- PMVP 2013
- CNTB 2012
- Country
- PMVP United States
- CNTB United States
- Employees
- PMVP N/A
- CNTB N/A
- Industry
- PMVP Medicinal Chemicals and Botanical Products
- CNTB Biotechnology: Pharmaceutical Preparations
- Sector
- PMVP Health Care
- CNTB Health Care
- Exchange
- PMVP Nasdaq
- CNTB Nasdaq
- Market Cap
- PMVP 76.8M
- CNTB 90.3M
- IPO Year
- PMVP 2020
- CNTB 2021
- Fundamental
- Price
- PMVP $1.42
- CNTB N/A
- Analyst Decision
- PMVP Strong Buy
- CNTB Strong Buy
- Analyst Count
- PMVP 1
- CNTB 2
- Target Price
- PMVP $5.00
- CNTB $7.50
- AVG Volume (30 Days)
- PMVP 949.9K
- CNTB 88.0K
- Earning Date
- PMVP 11-06-2025
- CNTB 11-13-2025
- Dividend Yield
- PMVP N/A
- CNTB N/A
- EPS Growth
- PMVP N/A
- CNTB N/A
- EPS
- PMVP N/A
- CNTB N/A
- Revenue
- PMVP N/A
- CNTB $1,965,000.00
- Revenue This Year
- PMVP N/A
- CNTB N/A
- Revenue Next Year
- PMVP N/A
- CNTB $453,067.90
- P/E Ratio
- PMVP N/A
- CNTB N/A
- Revenue Growth
- PMVP N/A
- CNTB N/A
- 52 Week Low
- PMVP $0.81
- CNTB $1.23
- 52 Week High
- PMVP $1.84
- CNTB $2.20
- Technical
- Relative Strength Index (RSI)
- PMVP 50.54
- CNTB 58.99
- Support Level
- PMVP $1.36
- CNTB $1.36
- Resistance Level
- PMVP $1.49
- CNTB $1.88
- Average True Range (ATR)
- PMVP 0.08
- CNTB 0.15
- MACD
- PMVP 0.01
- CNTB 0.04
- Stochastic Oscillator
- PMVP 57.41
- CNTB 99.48
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.